These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B). Stemler J; Yeghiazaryan L; Stephan C; Mohn KG; Carcas-Sansuan AJ; Rodriguez ER; Moltó J; Mitxeltorena IV; Welte T; Zablockienė B; Akova M; Bethe U; Heringer S; Salmanton-García J; Jeck J; Tischmann L; Zarrouk M; Cüppers A; Biehl LM; Grothe J; Mellinghoff SC; Nacov JA; Neuhann JM; Sprute R; Frías-Iniesta J; Negi R; Gaillard C; Saini G; León AG; Mallon PWG; Lammens C; Hotterbeekx A; Loens K; Malhotra-Kumar S; Goossens H; Kumar-Singh S; König F; Posch M; Koehler P; Cornely OA; Int J Infect Dis; 2024 Sep; 146():107161. PubMed ID: 38992789 [TBL] [Abstract][Full Text] [Related]
11. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. Rabinowich L; Grupper A; Baruch R; Ben-Yehoyada M; Halperin T; Turner D; Katchman E; Levi S; Houri I; Lubezky N; Shibolet O; Katchman H J Hepatol; 2021 Aug; 75(2):435-438. PubMed ID: 33892006 [TBL] [Abstract][Full Text] [Related]
12. The Impact of Time between Booster Doses on Humoral Immune Response in Solid Organ Transplant Recipients Vaccinated with BNT162b2 Vaccines. Hamm SR; Loft JA; Pérez-Alós L; Heftdal LD; Hansen CB; Møller DL; Pries-Heje MM; Hasselbalch RB; Fogh K; Hald A; Ostrowski SR; Frikke-Schmidt R; Sørensen E; Hilsted L; Bundgaard H; Garred P; Iversen K; Perch M; Sørensen SS; Rasmussen A; Sabin CA; Nielsen SD Viruses; 2024 May; 16(6):. PubMed ID: 38932153 [TBL] [Abstract][Full Text] [Related]
13. Humoral Response after SARS-CoV-2 mRNA Vaccination in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients. Danthu C; Hantz S; Dahlem A; Duval M; Ba B; Guibbert M; El Ouafi Z; Ponsard S; Berrahal I; Achard JM; Bocquentin F; Allot V; Rerolle JP; Alain S; Touré F J Am Soc Nephrol; 2021 Sep; 32(9):2153-2158. PubMed ID: 34135083 [TBL] [Abstract][Full Text] [Related]
14. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185 [TBL] [Abstract][Full Text] [Related]
15. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease. Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958 [TBL] [Abstract][Full Text] [Related]
16. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study. Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273 [TBL] [Abstract][Full Text] [Related]
17. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients. Massa F; Cremoni M; Gérard A; Grabsi H; Rogier L; Blois M; Couzin C; Hassen NB; Rouleau M; Barbosa S; Martinuzzi E; Fayada J; Bernard G; Favre G; Hofman P; Esnault VLM; Czerkinsky C; Seitz-Polski B; Glaichenhaus N; Sicard A EBioMedicine; 2021 Nov; 73():103679. PubMed ID: 34763205 [TBL] [Abstract][Full Text] [Related]
18. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection. Gobbi F; Buonfrate D; Moro L; Rodari P; Piubelli C; Caldrer S; Riccetti S; Sinigaglia A; Barzon L Viruses; 2021 Mar; 13(3):. PubMed ID: 33807957 [TBL] [Abstract][Full Text] [Related]
19. PMMA dialyzers modulate both humoral and cell-mediate immune response to anti-COVID-19 vaccine (BNT162b2) in a cohort of chronic hemodialyzed patients. Castellano G; Netti GS; Cantaluppi V; Losappio V; Spadaccino F; Ranieri E; Marengo M; Borzumati M; Alfieri C; Stallone G Sci Rep; 2024 May; 14(1):12217. PubMed ID: 38806543 [TBL] [Abstract][Full Text] [Related]